Heart failure & cardiomyopathiesMeta-analysis
Frailty Patterns, Reversibility, and Outcomes With a Magnetically Levitated Left Ventricular Assist Device
- Pooled analysis of the MOMENTUM 3 trial portfolio and ARIES-HM3 trial
Authors' conclusion
Frailty is highly prevalent among patients undergoing LVAD implantation but is often dynamic and partially reversible after restoration of circulatory support.
Study context
- Population
- HeartMate 3 left ventricular assist device (LVAD) recipients with advanced heart failure (HF)
- Participants
- 2,724 participants
- Comparison
- Frailty severity categories
- Outcome
- Composite of:
- Death
- Hemocompatibility-related adverse events
- Renal dysfunction
- Right HF
Pooled result
As reported in the abstract
Hazard ratio
6.26
95% CI 2.32–16.90
Severely frail vs Nonfrail
HR 6.26 (95% CI 2.32–16.90)
- Frailty at baseline
- 95%
Further pooled results
| Outcome | rate ratio (95% CI) | |
|---|---|---|
| Frailty reversibility after LVAD implantation · 3 months · subsequent primary endpoint | 0.53 (0.36–0.79) | |
| 0.20.5125Rate ratio (log scale) |
- Frailty reversibility after LVAD implantation — Recovery to a nonfrail state
- 15%
Frailty reversibility after LVAD implantation · 3 months
- Greatest absolute frailty reductions with severe baseline frailty
Multivariable model predicting recovery from frailty
- AUC
- 0.78-0.81
Original publication
Frailty Patterns, Reversibility, and Outcomes With a Magnetically Levitated Left Ventricular Assist Device. JACC Heart Fail. Published 1 September 2026. doi:10.1016/j.jchf.2026.103313
Summarised from the published abstract; every number is checked against it